Rosacea

An expert offers insights into the who, how, and when of these combined therapies.

At the SPD 2022 47th Annual Meeting, a poster session looks at the updated guidelines for rosacea, and whether they are inclusive of children.

From pediatric dermatology quizzes to the latest news in telederm to practical pearls on atopic dermatitis, alopecia, and vitiligo, there’s a lot going on at the SPD 2022 47th Annual Meeting, this year in Indianapolis, Indiana.

James Q. Del Rosso, DO, highlights different rosacea treatment options in his session at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.

In a session for the 2022 Fall Clinical Dermatology Conference for PAs & NPs, held June 3 to 5, in Scottsdale, Arizona, James Q. Del Rosso, DO, delves into new knowledge on the characteristics of this challenging skin condition.

In vitro and in vivo research sheds light on medication’s mechanism of action.

Julie Harper, MD, talks about the Epsolay drug approval that happened April 25. She dives into its mechanism of action, its potential as both a first line treatment or combination therapy, and what she would like to see next in its research.

Gina Mangin, PA-C, and James Treat, MD, dive into the intricacies of acne and rosacea, going beyond the surface of both skin conditions and giving important treatment tips at the 2022 New Wave Dermatology Conference.

Sol-Gel Technologies and Galderma announce the FDA approval of the 5% benzoyl peroxide, cream for the treatment of inflammatory lesions of rosacea.

Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, who dives into what is currently lacking is rosacea patient care, how the new mechanisms of action of these potential treatments will better address current struggles, and more.